Twitter | Search | |
Search Refresh
Aetion, Inc. 59s
In our new white paper, “RWE and HTA decision-making,” Ashley Jaksa discusses the value of for HTAs, opportunities for increased use, and implications for biopharma, featuring insights from Dr. Jens Grueger, President-elect of :
Reply Retweet Like
Robert Harrington 4h
As you have noted, there is no substitute for randomization when one wants to understand treatment effect. doesn’t exclude RCTs. Pick the right design and methods for the question.
Reply Retweet Like
Toby Eyre Dec 9
EFS 3 months in unselected pts EFS still only those that received cells (91/116 pts - most of diff progressed pre-CAR-T) This is genuine real world data across with national coverage Innovate & exciting or a bad version of palliative care for most?
Reply Retweet Like
Mrs. Sirna 4h
Last week’s Munch and Read—enjoying good books with good friends🙂
Reply Retweet Like
Mrs. Sirna 4h
Thank you Mrs. Munstermann for a fun “Breakout” session! The kids really enjoyed it! 😀
Reply Retweet Like
Art Sedrakyan Dec 10
Excellent discussion at US-Japan forum about limitations and advantages of trials and for evaluation. over 150 regulators and stakeholder participants
Reply Retweet Like
Xcenda 23h
We're very honored to be recognized as "Audience Favorite" in Part II of the 1st Annual HE Innovation Webinar Series! Thank you to all who joined us and our fellow innovators on the webinar. , ,
Reply Retweet Like
Adaptive Biotech 3h
confirms the ability to use to assess patient prognosis or depth of response to therapy. Dr. Mohammad Hussaini discussed the “tsunami” of MRD data that’s being generated during his poster session at .
Reply Retweet Like
chadi nabhan MD, MBA Dec 9
Getting ready to moderate oral session on outcomes research for and in room 415A along side my friend Stop by; we have 6 excellent abstracts.
Reply Retweet Like
Razorwire® Energy Gaming Fuel Dec 7
Want to give our RWE PLAYER 1 GAMING FUEL a try? 👀 . Your in LUCK🍀 . You can grab a 🔥FREE🔥 sample at our website for the best energy and focus!! . . .
Reply Retweet Like
Thomas Welch Dec 10
Exactly. We need for post-market surveillance.
Reply Retweet Like
NYLandscaper Dec 6
In this labor crisis climate, seasonal businesses don’t stand a chance. We advertise all year long.We have no applicants looking for short term work. There r very few job seekers & they obviously prefer year round work. Double the visa cap & perm reinstate the .
Reply Retweet Like
Thomas Welch Dec 10
is the best solution for this too.
Reply Retweet Like
ARM 5h
“We need data to supplement the approval processes by building on the registries that exist” - in her closing remarks at our meeting, ⁦⁩ addresses the need to better coordinate the use and collection of across Europe to progress
Reply Retweet Like
Hiro Ohtsu 6h
Thank you . Many keypersons were learning about , , and important of international collaborations.
Reply Retweet Like
Art Sedrakyan 12h
Another day of discussions at successful launch of in Japan. Fantastic talks by and over 200 Various registry leaders in Japan participating in the meeting
Reply Retweet Like
Verantos 5h
The strategic use of can help overcome the shortcomings of classic randomized clinical trial () design. Leading clinical trial is strengthening its commitment to, and capabilities in, advanced RWE.
Reply Retweet Like
Eric James Dec 9
Fear Defeats More People Than Any One Thing In The World
Reply Retweet Like
Hiro Ohtsu 6h
Reply Retweet Like
TNI Dec 9
Tomorrow the Dutch Parliament will vote to phase-out . But German coal giants and are preparing billion euro compensation claims. Watch and share our new video on this latest heist by the fossil industry
Reply Retweet Like